Pharma Journalist -

A new way to plan radiotherapy could help shape treatment away from sensitive organs near tumours to reduce side-effects, a new study shows. The technique has been developed by…
Read More...

BiomX Ltd. announced the closing of a $32 million series B equity financing. The financing was led by existing investors OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda…
Read More...

NanoSphere Health Sciences Inc. announced the signing of a definitive Licensing Agreement with Oregon cannabis company Cascade Pure, LLC. The Agreement gives Cascade Pure the exclusive…
Read More...

Knight Therapeutics Inc. announced it has entered into a secured loan and exclusive License Agreement with privately-held Triumvira Immunologics. The US$5 million secured loan has a…
Read More...

Indivior PLC announced that its U.S. affiliate, Indivior Inc., has launched an authorized generic version of SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) in the U.S. The…
Read More...

Torque, a clinical-stage immuno-oncology company developing first-in-class Deep Primed T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced that…
Read More...

At SMi’s 2019 Pre-Filled Syringes East Coast USA Conference, industry leaders will meet in Boston to share their insights on best design practice, drug compatibility within the whole…
Read More...

Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in…
Read More...

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for upadacitinib for the treatment of adult…
Read More...